A multi-centre clinical study of the CCLG-APL 2024 protocol

A multi-centre clinical study of the CCLG-APL 2024 protocol - CCLG-APL 2024 protocol

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400085721

Enrollment

Unknown

Registered

2024-06-17

Start date

2024-06-20

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute promyelocytic leukemia in children and adolescents

Interventions

CCLG-APL 2024 protocol:Targeted therapy with retinoic acid and arsenic in combination with venetoclax

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: (1) Fulfilment of diagnostic criteria: PML-RARa positivity and/or with t(15;17)(q22;q21) chromosomal translocation; (2) Age = 18 years; (3) Normal cardiac function; (4) Obtained informed consent signed by the patient or guardian.

Exclusion criteria

Exclusion criteria: (1) Children with relapsed APL (children with relapsed APL use the relapse protocol). (2) Those who are allergic to retinoic acid, arsenic, and venetoclax involved in this protocol. (3) Children and guardians who cannot understand or do not comply with the study protocol. (4) Participants in other clinical studies during the same period.

Design outcomes

Primary

Measure	Time frame
Overall survival;Event-free survival;	—

Secondary

Measure	Time frame
Time to achieve hematologic complete remission;Time to achieve molecular complete remission;Early mortality;Cumulative disease relapse rate;	—

Countries

China

Contacts

Public ContactHuyong Zheng

Beijing Children's Hospital, Capital Medical University

zhenghuyong@bch.com.cn+86 133 7011 5036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026